230 related articles for article (PubMed ID: 24475247)
1. Identification of a recurrent STRN/ALK fusion in thyroid carcinomas.
Pérot G; Soubeyran I; Ribeiro A; Bonhomme B; Savagner F; Boutet-Bouzamondo N; Hostein I; Bonichon F; Godbert Y; Chibon F
PLoS One; 2014; 9(1):e87170. PubMed ID: 24475247
[TBL] [Abstract][Full Text] [Related]
2. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer.
Kelly LM; Barila G; Liu P; Evdokimova VN; Trivedi S; Panebianco F; Gandhi M; Carty SE; Hodak SP; Luo J; Dacic S; Yu YP; Nikiforova MN; Ferris RL; Altschuler DL; Nikiforov YE
Proc Natl Acad Sci U S A; 2014 Mar; 111(11):4233-8. PubMed ID: 24613930
[TBL] [Abstract][Full Text] [Related]
3. Mouse Model of Thyroid Cancer Progression and Dedifferentiation Driven by STRN-ALK Expression and Loss of p53: Evidence for the Existence of Two Types of Poorly Differentiated Carcinoma.
Nikitski AV; Rominski SL; Condello V; Kaya C; Wankhede M; Panebianco F; Yang H; Altschuler DL; Nikiforov YE
Thyroid; 2019 Oct; 29(10):1425-1437. PubMed ID: 31298630
[No Abstract] [Full Text] [Related]
4. Inhibition of ALK-Signaling Overcomes STRN-ALK-Induced Downregulation of the Sodium Iodine Symporter and Restores Radioiodine Uptake in Thyroid Cells.
Nikitski AV; Condello V; Divakaran SS; Nikiforov YE
Thyroid; 2023 Apr; 33(4):464-473. PubMed ID: 36585857
[No Abstract] [Full Text] [Related]
5.
Bastos AU; de Jesus AC; Cerutti JM
Eur J Endocrinol; 2018 Jan; 178(1):83-91. PubMed ID: 29046324
[TBL] [Abstract][Full Text] [Related]
6. Coexistence of a secondary STRN-ALK, EML4-ALK double-fusion variant in a lung adenocarcinoma patient with EGFR mutation: a case report.
Zeng Q; Gao H; Zhang L; Qin S; Gu Y; Chen Q
Anticancer Drugs; 2021 Sep; 32(8):890-893. PubMed ID: 34232939
[TBL] [Abstract][Full Text] [Related]
7. Mouse Model of Poorly Differentiated Thyroid Carcinoma Driven by STRN-ALK Fusion.
Nikitski AV; Rominski SL; Wankhede M; Kelly LM; Panebianco F; Barila G; Altschuler DL; Nikiforov YE
Am J Pathol; 2018 Nov; 188(11):2653-2661. PubMed ID: 30125543
[TBL] [Abstract][Full Text] [Related]
8. An Anaplastic Lymphoma Kinase Immunohistochemistry-Negative but Fluorescence In Situ Hybridization-Positive Lung Adenocarcinoma Is Resistant to Crizotinib.
Shi R; Varella-Garcia M; Li M; Ludkovski O; Danesh A; Ng C; Pham NA; Pugh T; Shepherd FA; Tsao MS
J Thorac Oncol; 2016 Dec; 11(12):2248-2252. PubMed ID: 27613526
[TBL] [Abstract][Full Text] [Related]
9. Quantification of Anaplastic Lymphoma Kinase Protein Expression in Non-Small Cell Lung Cancer Tissues from Patients Treated with Crizotinib.
Hembrough T; Liao WL; Hartley CP; Ma PC; Velcheti V; Lanigan C; Thyparambil S; An E; Monga M; Krizman D; Burrows J; Tafe LJ
Clin Chem; 2016 Jan; 62(1):252-61. PubMed ID: 26585927
[TBL] [Abstract][Full Text] [Related]
10. Characterization of thyroid cancer driven by known and novel ALK fusions.
Panebianco F; Nikitski AV; Nikiforova MN; Kaya C; Yip L; Condello V; Wald AI; Nikiforov YE; Chiosea SI
Endocr Relat Cancer; 2019 Nov; 26(11):803-814. PubMed ID: 31539879
[TBL] [Abstract][Full Text] [Related]
11. Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants.
Cha YJ; Kim HR; Shim HS
J Transl Med; 2016 Oct; 14(1):296. PubMed ID: 27756333
[TBL] [Abstract][Full Text] [Related]
12. A Novel Malignant Peritoneal Mesothelioma with STRN Exon 2 and ALK Exon 20: A Case Report and Literature Review.
Miyagawa C; Takaya H; Sakai K; Nishio K; Konishi M; Minamiguchi S; Shimada T; Matsumura N
Oncologist; 2021 May; 26(5):356-361. PubMed ID: 33555117
[TBL] [Abstract][Full Text] [Related]
13. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target.
Demeure MJ; Aziz M; Rosenberg R; Gurley SD; Bussey KJ; Carpten JD
World J Surg; 2014 Jun; 38(6):1296-305. PubMed ID: 24633422
[TBL] [Abstract][Full Text] [Related]
14. Detection of STRN-ALK fusion in thyroid nodules with indeterminate cytopathology facilitates papillary thyroid cancer diagnosis.
Jurkiewicz M; Cimic A; Murty VV; Kuo JH; Hsiao S; Fazlollahi L; Fernandes H
Diagn Cytopathol; 2021 Apr; 49(4):E146-E151. PubMed ID: 33085842
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological features and immunohistochemical utility of NTRK-, ALK-, and ROS1-rearranged papillary thyroid carcinomas and anaplastic thyroid carcinomas.
Nozaki Y; Yamamoto H; Iwasaki T; Sato M; Jiromaru R; Hongo T; Yasumatsu R; Oda Y
Hum Pathol; 2020 Dec; 106():82-92. PubMed ID: 32980422
[TBL] [Abstract][Full Text] [Related]
16. Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.
Godbert Y; Henriques de Figueiredo B; Bonichon F; Chibon F; Hostein I; Pérot G; Dupin C; Daubech A; Belleannée G; Gros A; Italiano A; Soubeyran I
J Clin Oncol; 2015 Jul; 33(20):e84-7. PubMed ID: 24687827
[No Abstract] [Full Text] [Related]
17. Comprehensive Genomic Profiling Identifies a Subset of Crizotinib-Responsive ALK-Rearranged Non-Small Cell Lung Cancer Not Detected by Fluorescence In Situ Hybridization.
Ali SM; Hensing T; Schrock AB; Allen J; Sanford E; Gowen K; Kulkarni A; He J; Suh JH; Lipson D; Elvin JA; Yelensky R; Chalmers Z; Chmielecki J; Peled N; Klempner SJ; Firozvi K; Frampton GM; Molina JR; Menon S; Brahmer JR; MacMahon H; Nowak J; Ou SH; Zauderer M; Ladanyi M; Zakowski M; Fischbach N; Ross JS; Stephens PJ; Miller VA; Wakelee H; Ganesan S; Salgia R
Oncologist; 2016 Jun; 21(6):762-70. PubMed ID: 27245569
[TBL] [Abstract][Full Text] [Related]
18. Responses to crizotinib in patients with ALK-positive lung adenocarcinoma who tested immunohistochemistry (IHC)-positive and fluorescence in situ hybridization (FISH)-negative.
Ma D; Wang Z; Yang L; Mu X; Wang Y; Zhao X; Li J; Lin D
Oncotarget; 2016 Sep; 7(39):64410-64420. PubMed ID: 27418132
[TBL] [Abstract][Full Text] [Related]
19. Comparison of IHC, FISH and RT-PCR methods for detection of ALK rearrangements in 312 non-small cell lung cancer patients in Taiwan.
Wu YC; Chang IC; Wang CL; Chen TD; Chen YT; Liu HP; Chu Y; Chiu YT; Wu TH; Chou LH; Chen YR; Huang SF
PLoS One; 2013; 8(8):e70839. PubMed ID: 23951022
[TBL] [Abstract][Full Text] [Related]
20. Two Cases of Renal Cell Carcinoma Harboring a Novel STRN-ALK Fusion Gene.
Kusano H; Togashi Y; Akiba J; Moriya F; Baba K; Matsuzaki N; Yuba Y; Shiraishi Y; Kanamaru H; Kuroda N; Sakata S; Takeuchi K; Yano H
Am J Surg Pathol; 2016 Jun; 40(6):761-9. PubMed ID: 26848800
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]